Clinical trials: Clopidogrel
Pharmacodynamics
Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
The purpose of this study is to compare the pharmacodynamic effect of clopidogrel on the platelet inhibition and the pharmacokinetic profiles of clopidogrel carboxylic acid metabolite between generic and reference clopidogrel…
- Trial name
- NCT02010632
- Testing
- Generic clopidogrel product Apolets®, Original clopidogrel product Plavix®
- Where
- Thailand
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Khon Kaen University
Myocardial Infarction
Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation.
- Trial name
- AFFECT EV (NCT02931045)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Platelet Dysfunction, Von Willebrand Diseases
Clinical Performance Evaluation of T-TAS 01 PL Chip
This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth.
- Conditions
- Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
- Trial name
- NCT03621020
- Testing
- T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
- Where
- 6 sites in United States, France
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Hikari Dx, Inc.
Thromboembolic Stroke, Aspirin
The Prevention of Thromboembolic Complications Associated With Coil Embolization
Clopidogrel has been to be reported to be superior to aspirin for the prevention of thromboembolic complications associated with coil embolization in patients with ruptured aneurysms.
- Conditions
- Thromboembolic Stroke, Aspirin, Clopidogrel, Coil Embolization
- Trial name
- NCT05512546
- Testing
- Aspir-Low Pill
- Where
- Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Muhammad Hassan
Diabetes Mellitus Type 2
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open, dose-escalating study of PF-07081532 in patients with Type 2 diabetes on metformin (Parts A and C).
- Trial name
- NCT04305587
- Testing
- PF-07081532, Clopidogrel
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg
The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered…
- Trial name
- NCT00648947
- Testing
- Clopidogrel Bisulfate Tablets 75 mg, Plavix® Tablets 75 mg
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Drug Interaction of Clopidogrel
Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel
Clopidogrel is a platelets inhibitor that is widely used particularly during and after acute coronary events and coronary interventions. Several studies have shown that some patients are resistant to clopidogrel.
- Trial name
- NCT01269333
- Testing
- omeprazole, fluvoxamine
- Where
- Israel
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Endotoxemia
Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
Rationale: In patients suffering a myocardial infarction the P2Y12 receptor antagonists prasugrel and ticagrelor improve outcome and prognosis compared to clopidogrel.
- Trial name
- NCT02612480
- Testing
- ticagrelor, Clopidogrel, Acetylsalicylic acid lysinate
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Bioequivalence
Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition
To compare the rate and extent of absorption of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® (clopidogrel) 75 mg tablet under fasting condition.
- Trial name
- NCT05186129
- Testing
- Clopid® 75 mg Tablet, Plavix® 75mg Tablet
- Where
- Pakistan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Center for Bioequivalence Studies and Clinical Research
Coronary Artery Disease
Healthy Volunteer Study of Clopidogrel and Rifampicin
The principal research question is: Can platelet P2Y12 receptor blockade by the antithrombotic drug clopidogrel be significantly enhanced by coadministration of the antibiotic rifampicin? Clopidogrel is an antithrombotic drug in…
- Trial name
- NCT00696566
- Testing
- Clopidogrel and Rifampicin
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Acute Ischemic Stroke
Evaluation Of HUK in Acute Stroke Patients: MRS and CTP
Background: Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality worldwide. Human urinary kallidinogenase (HUK), a glycoprotein extracted from male urine currently used in China for enhancing cerebral…
- Trial name
- NCT03431909
- Testing
- Human urinary kallidinogenase (HUK), aspirin® , clopidogrel® , atorvastatin®
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Myocardial Infarction, Coronary Artery Diseases
Physical and Chemical Study of Atherosclerosis Mechanisms
Study the mechanisms of atherosclerosis based on a comparative study of physical and chemical properties of lipid tissues at various localization with subsequent development of concept of treatment and prevention.
- Conditions
- Myocardial Infarction, Coronary Artery Diseases, Diabetes Mellitus, Type 2, Atherosclerosis of Femoral Artery
- Trial name
- PCSAM (NCT01700075)
- Testing
- Conventional treatment, Weight loss treatment
- Where
- Kazakhstan
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Nazarbayev University
Platelet Function and Reactivity Tests
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
- Trial name
- NCT06933056
- Testing
- Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Bioequivalence, AUC, Cmax, Pharmacokinetics
Clopidogrel Bioequivalence Study in Healthy Subjects
This study will be an open-label, randomised, three-way crossover study in healthy male and female subjects, performed at a single centre.
- Trial name
- NCT02185534
- Testing
- Clopidogrel
- Where
- Germany
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants
This study aims to evaluate the influence of tegoprazan on the pharmacodynamics of clopidogrel according to CYP2C19 genotypes following co-administration of tegoprazan and clopidogrel in healthy male volunteers.
- Trial name
- NCT03814642
- Testing
- Clopidogrel 75 mg, Tegoprazan 50 mg, Esomeprazole 20 mg
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy
Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects
Study to investigate the relative bioavailability of concomitant administration of clopidogrel and telmisartan (Test 1) relative to the bioavailability of SR26334 alone (Reference 1), and relative to the bioavailability of…
- Trial name
- NCT02262650
- Testing
- Telmisartan, Clopidogrel
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim